Pediatric Cancer Biomarkers Market Size, Share & Trends Analysis Report By Indication (Lymphoma, Neuroblastoma, Leukemia, CNS Tumors, Others), By Biomarker (Neuron-Specific enolase (NSE), Alpha-Fetoprotien (AFP), ALK (Anaplastic lymphoma receptor tyrosine kinase gene), CD19, CD20, CD22, Others), By End-User (Hospitals, Oncology Centers, Research Institutions, Diagnostic Laboratories) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Pediatric Cancer Biomarkers Market Size

The global pediatric cancer biomarkers market size was valued at USD 971.01 million in 2025 and is projected to grow from USD 1040.92 million in 2026 to USD 1815.42 million by 2034, registering a CAGR of 7.2% during the forecast period from 2026 to 2034. North America dominated the pediatric cancer biomarkers market with a market share of 38.2% in 2025.

A biomarker is a biological molecule found in blood, tissues, and other bodily fluids that serves as an indicator of a disease or condition. With the rising prevalence of pediatric carcinos globally, there has been a notable increase in demand for the development of pediatric cancer biomarkers.

Moreover, ongoing innovations in molecular research aimed at the early detection of carcinos in children are significantly driving the market growth. For example, in March 2024, scientists at the University of California, San Francisco, discovered a universal and critical biomarker for neuroblastoma, which could also become a promising target for new treatments.

Indication Analysis

Leukemia segment dominates the market with the highest market revenue due to its high prevalence among children. According to the Children's Hospital of Philadelphia, approximately 4,000 children are diagnosed with cancer annually in the U.S., with one-third of these cases being leukemia. This growing incidence drives the demand for biomarkers to enable early detection and monitor carcinos progression effectively, aiding in timely treatment and diagnosis.

• For example, in November 2024, research by 17 global partner institutions and Professor Terry Dwyer identified molecular markers in blood linked to the progression of acute lymphoblastic leukemia (ALL), enhancing early diagnostic capabilities.

Request Customizationto receive a tailored report.

biomarker Analysis

CD19, CD20, CD22 segment dominates the market with the highest market revenue due to their critical role in advanced carcinos therapies. CD19, in particular, is a pivotal target for CAR-T cell therapies, such as axicabtagene ciloleucel, used in treating refractory or relapsed B-cell lymphoma and leukemia. These biomarkers enable precise, targeted treatments that improve outcomes for pediatric patients.

• For instance, therapies targeting CD19 have shown significant success in treating aggressive cancers, making this segment a key contributor to the pediatric carcinos biomarkers market.

end-User Analysis

Hospitals dominate the global market as they are the primary centers for cancer diagnosis and treatment. With specialized pediatric oncology departments, hospitals offer advanced diagnostic tools, trained staff, and state-of-the-art facilities, enabling comprehensive care. Moreover, many clinical research studies on biomarkers are conducted in hospital settings, further driving their adoption. This infrastructure allows hospitals to cater to a large pediatric population, ensuring accurate diagnostics and personalized treatment plans, making them a cornerstone of the market.

Speak to an Analystto discuss market opportunities.

regional Insights

North America leads the global market, driven by significant investments in childhood cancer initiatives. Organizations like the American Cancer Society Cancer Action Network (ACS CAN) are advocating for substantial funding to improve outcomes for children with carcinos.

• In January 2024, ACS CAN urged Congress to allocate $30 million for the STAR Act, supporting survivorship, treatment access, and research; $50 million for the Childhood Cancer Data Initiative (CCDI); and $51 billion for the NIH, including $10 billion for cancer research at the National Cancer Institute (NCI).

These investments aim to enhance research, improve treatment options, and support childhood cancer survivors, strengthening North America’s market dominance.

• Canada’s market is fueled by government investments in pediatric cancer research and rising cases. Data from the Government of Canada reveals nearly 10,000 children live with carcinos, with 1,500 new cases diagnosed annually. This highlights the urgent need for biomarkers to enhance early detection and effective treatment strategies.

U.s. Pediatric Cancer Biomarkers Market Trends

• The U.S. dominates the regional market, driven by a focus on rare cancer research and the rising prevalence of pediatric cancer. According to Congressionally Directed Medical Research, cancer is the leading cause of death in children, with over 1,600 deaths annually, emphasizing the need for innovative biomarkers to improve early detection and treatment outcomes.

Unlock Regional Insightsto access country-level data, & regional trends.

Asia-Pacific Pediatric Cancer Biomarkers Market Trends

The Asia-Pacific region is the fastest-growing market, fueled by the rising incidence of pediatric cancer in countries like India and China. Improved healthcare infrastructure and supportive government initiatives are driving this growth. In India, public-private partnerships under the National Health Mission have significantly strengthened healthcare policies, expanding access to diagnostics and treatment.

Moreover, increased awareness and investments in healthcare technologies are further boosting the adoption of cancer biomarkers in this region. This rapid growth positions Asia-Pacific as a critical player in the global market.

• India is witnessing rapid growth in the market, with nearly 50,000 children diagnosed annually, according to the Indian Cancer Society. The increasing number of cases emphasizes the demand for innovative biomarkers to enable early detection and improve treatment effectiveness in the country.
• China’s market is expanding rapidly due to a rising incidence of childhood cancer. With 22,000 new cases annually and a 2.5% annual increase in malignant tumors among children under 14, the demand for pediatric cancer biomarkers is growing despite limited treatment options for solid tumors.
• Japan’s market is driven by the increasing prevalence of pediatric cancer. According to the Japan Children’s Cancer Group, 2,500 children are diagnosed annually, with cancer being a significant cause of mortality. This highlights the need for advanced biomarkers to improve treatment outcomes and survival rates.

Uk Market Trends

• The UK market is expanding due to the increasing prevalence of pediatric cancer. According to the Children’s Cancer and Leukemia Group, approximately 1,635 children are diagnosed with carcinos each year. This growing incidence is driving demand for advanced cancer biomarkers, aiding in early diagnosis and personalized treatments to improve survival rates.

Germany Market Trends

• Germany’s market growth is driven by the rising incidence of pediatric cancer. The Journal of Health Monitoring reports 2,250 new cases annually among children under 18, with leukemia and lymphoma accounting for 50%. These figures underscore the importance of biomarkers for accurate diagnosis and improved outcomes.

Australia Market Trends

• Australia’s market is growing due to rising childhood cancer cases. The HUDSON Institute of Medical Research reports 1,000 new diagnoses annually, with 5,600 children undergoing treatment. This demand for effective biomarkers underscores their critical role in advancing early diagnosis and therapeutic strategies.

List of Key and Emerging Players in Pediatric Cancer Biomarkers Market